Early postoperative versus delayed radiotherapy in bladder sparring treatment of patients with high-grade urinary bladder cancer

Keywords: high-grade urinary bladder cancer, bladder sparring surgery, radiotherapy, survival.


Objective. To study the prevalence and effect on the survival of high grade bladder cancer (G3 UBC) patients of external beam radiotherapy delivered in early or delayed period after the bladder preserving surgery.

Materials and methods. We retrospectively studied the medical records of 522 G3 UBC patients, out of whom 101 (19.3%) were treated radically with organ preserving surgery, followed by the radiotherapy. All patients were split in group of early (upto 3 months postoperatively) and delayed radiotherapy. The radiotherapy was performed on the Oncor Impression Plus linear accelerator with total radiation dose of 62 Gy and daily fraction of 2Gy. Kaplan-Meier survival curves were built to test the hypothesis of equality of survival of patients of both groups.

Results. The group of early radiotherapy accounted for 70.3% patients versus 29.7% in group of delayed radiotherapy. The survival in groups per Stages II, III and IV of G3 UBC was 48.6 vs. 26.4 months, 43.9 vs. 32.7 mo., 25.4 vs. 46.9 mo., respectively. The overall survival in both groups was 43 vs. 36 months (p=0.57).

Conclusion. Majority of G3 UBC patients (70.3%) were treated with early radiotherapy following bladder sparring surgery. Survival of patients with delayed radiotherapy is worse than of patients with early radiotherapy, 36 vs. 43 months (p=0,57).

Author Biography

P. G. Yakovlev, Clinical hospital “Feofaniya”, Kyiv, Ukraine

Yakovlev Pavlo, MD, PhD(Med)
Head of the Center of Urology and Oncourology,
Clinical Hospital “Feofaniya”,
21 Acad.Zabolotnogo Str., 03143, Kyiv, Ukraine.
+38 (044) 299-49-10,
E-mail: pavel_3@hotmail.com


Lewanski CR, Gullick WJ. Radiotherapy and cellular signalling. Lancet Oncol. 2001 Jun;2(6):366-70. doi: 10.1016/S1470-2045(00)00391-0. Erratum in: Lancet Oncol 2001 Jul;2(7):455. PMID: 11905753.

Velic D, Couturier AM, Ferreira MT, Rodrigue A, Poirier GG, Fleury F, et al. DNA Damage Signalling and Repair Inhibitors: The Long-Sought-After Achilles' Heel of Cancer. Biomolecules. 2015 Nov 20;5(4):3204-59. doi: 10.3390/biom5043204. PMID: 26610585; PMCID: PMC4693276.

Shao C, Folkard M, Michael BD, Prise KM. Targeted cytoplasmic irradiation induces bystander responses. Proc Natl Acad Sci U S A. 2004 Sep 14;101(37):13495-500. doi: 10.1073/pnas.0404930101. Epub 2004 Sep 2. PMID: 15345742; PMCID: PMC518785.

Pilones KA, Vanpouille-Box C, Demaria S. Combination of radiotherapy and immune checkpoint inhibitors. Semin Radiat Oncol. 2015 Jan;25(1):28-33. doi: 10.1016/j.semradonc.2014.07.004. PMID: 25481263.

Wang JS, Wang HJ, Qian HL. Biological effects of radiation on cancer cells. Mil Med Res. 2018;5(1):20. doi: 10.1186/s40779-018-0167-4.

Gild P, Nguyen DD, Fletcher SA, Cole AP, Lipsitz SR, Kibel AS, et al. Contemporary Survival Rates for Muscle-Invasive Bladder Cancer Treated With Definitive or Non-Definitive Therapy. Clin Genitourin Cancer. 2019 Jun;17(3):e488-e493. doi: 10.1016/j.clgc.2019.01.009. Epub 2019 Jan 29. PMID: 30837209.

Ploussard G, Daneshmand S, Efstathiou JA, Herr HW, James ND, Rödel CM, et al. Critical analysis of bladder sparing with trimodal therapy in muscle-invasive bladder cancer: a systematic review. Eur Urol. 2014 Jul;66(1):120-37. doi: 10.1016/j.eururo.2014.02.038. Epub 2014 Feb 26. PMID: 24613684.

Nagao K, Hara T, Nishijima J, Shimizu K, Fujii N, Kobayashi K, et al. The Efficacy of Trimodal Chemoradiotherapy with Cisplatin as a Bladder-Preserving Strategy for the Treatment of Muscle-Invasive Bladder Cancer. Urol Int. 2017;99(4):446-452. doi: 10.1159/000477912. Epub 2017 Jun 21. PMID: 28628910.

Kulkarni GS, Hermanns T, Wei Y, Bhindi B, Satkunasivam R, Athanasopoulos P, et al. Propensity Score Analysis of Radical Cystectomy Versus Bladder-Sparing Trimodal Therapy in the Setting of a Multidisciplinary Bladder Cancer Clinic. J Clin Oncol. 2017 Jul 10;35(20):2299-2305. doi: 10.1200/JCO.2016.69.2327. Epub 2017 Apr 14. PMID: 28410011.

Russell CM, Lebastchi AH, Borza T, Spratt DE, Morgan TM. The Role of Transurethral Resection in Trimodal Therapy for Muscle-Invasive Bladder Cancer. Bladder Cancer. 2016 Oct 27;2(4):381-394. doi: 10.3233/BLC-160076. PMID: 28035319; PMCID: PMC5181666.

Bateni ZH, Pearce SM, Zainfeld D, Ballas L, Djaladat H, Schuckman AK, et al. National Practice Patterns and Overall Survival After Adjuvant Radiotherapy Following Radical Cystectomy for Urothelial Bladder Cancer in the USA, 2004-2013. Eur Urol Oncol. 2020 Jun;3(3):343-350. doi: 10.1016/j.euo.2018.11.010. Epub 2018 Dec 19. PMID: 31317867; PMCID: PMC7472657.

Kaushik D, Wang H, Michalek J, Liss MA, Liu Q, Jha RP, et al. Chemoradiation Vs Radical Cystectomy for Muscle-invasive Bladder Cancer: A Propensity Score-weighted Comparative Analysis Using the National Cancer Database. Urology. 2019 Nov;133:164-174. doi: 10.1016/j.urology.2019.05.062. Epub 2019 Aug 8. PMID: 31401220; PMCID: PMC6842694.

Vashistha V, Wang H, Mazzone A, Liss MA, Svatek RS, Schleicher M, et al. Radical Cystectomy Compared to Combined Modality Treatment for Muscle-Invasive Bladder Cancer: A Systematic Review and Meta-Analysis. Int J Radiat Oncol Biol Phys. 2017 Apr 1;97(5):1002-1020. doi: 10.1016/j.ijrobp.2016.11.056. Epub 2016 Dec 13. PMID: 28332983.

Pignot G, Sargos P. Place de la radiothérapie adjuvante après cystectomie pour les tumeurs de vessie infiltrant le muscle [Adjuvant radiotherapy after radical cystectomy for muscle-invasive bladder cancer]. Prog Urol. 2020 Dec 23:S1166-7087(20)30741-7. French. doi: 10.1016/j.purol.2020.12.003. Epub ahead of print. PMID: 33358467.

Hautmann RE, de Petriconi RC, Pfeiffer C, Volkmer BG. Radical cystectomy for urothelial carcinoma of the bladder without neoadjuvant or adjuvant therapy: long-term results in 1100 patients. Eur Urol. 2012 May;61(5):1039-47. doi: 10.1016/j.eururo.2012.02.028. Epub 2012 Feb 22. PMID: 22381169.

Christodouleas JP, Baumann BC, He J, Hwang WT, Tucker KN, Bekelman JE, et al. Optimizing bladder cancer locoregional failure risk stratification after radical cystectomy using SWOG 8710. Cancer. 2014 Apr 15;120(8):1272-80. doi: 10.1002/cncr.28544. Epub 2014 Jan 3. Erratum in: Cancer. 2015 Jan 1;121(1):162. Herr, Harry [added]. PMID: 24390799.

Sargos P, Baumann BC, Eapen LJ, Bahl A, Murthy V, Roubaud G, et al. Adjuvant radiotherapy for pathological high-risk muscle invasive bladder cancer: time to reconsider? Transl Androl Urol. 2016 Oct;5(5):702-710. doi: 10.21037/tau.2016.08.18. PMID: 27785427; PMCID: PMC5071208.

Mak RH, Hunt D, Shipley WU, Efstathiou JA, Tester WJ, Hagan MP, et al. Long-term outcomes in patients with muscle-invasive bladder cancer after selective bladder-preserving combined-modality therapy: a pooled analysis of Radiation Therapy Oncology Group protocols 8802, 8903, 9506, 9706, 9906, and 0233. J Clin Oncol. 2014 Dec 1;32(34):3801-9. doi: 10.1200/JCO.2014.57.5548. Epub 2014 Nov 3. Erratum in: J Clin Oncol. 2015 Mar 1;33(7):814. PMID: 25366678; PMCID: PMC4239302.

Fischer-Valuck BW, Michalski JM, Harton JG, Birtle A, Christodouleas JP, Efstathiou JA, et al Management of Muscle-Invasive Bladder Cancer During a Pandemic: Impact of Treatment Delay on Survival Outcomes for Patients Treated With Definitive Concurrent Chemoradiotherapy. Clin Genitourin Cancer. 2021 Feb;19(1):41-46.e1. doi: 10.1016/j.clgc.2020.06.005. Epub 2020 Jun 22. PMID: 33187904; PMCID: PMC7306737.

Wallis CJD, Novara G, Marandino L, Bex A, Kamat AM, Karnes RJ, et al. Risks from Deferring Treatment for Genitourinary Cancers: A Collaborative Review to Aid Triage and Management During the COVID-19 Pandemic. Eur Urol. 2020 Jul;78(1):29-42. doi: 10.1016/j.eururo.2020.04.063. Epub 2020 May 3. PMID: 32414626; PMCID: PMC7196384.

Hanna TP, King WD, Thibodeau S, Jalink M, Paulin GA, Harvey-Jones E, et al. Mortality due to cancer treatment delay: systematic review and meta-analysis. BMJ. 2020 Nov 4;371:m4087. doi: 10.1136/bmj.m4087. PMID: 33148535; PMCID: PMC7610021.

How to Cite
Yakovlev, P. G. (2020). Early postoperative versus delayed radiotherapy in bladder sparring treatment of patients with high-grade urinary bladder cancer. Klinicheskaia Khirurgiia, 87(9-10), 63-67. https://doi.org/10.26779/2522-1396.2020.9-10.63
General Problems of Surgery